Biodesix

Biodesix ROCE

The Return on Capital Employed (ROCE) of Biodesix (BDSX) as of Oct 21, 2026 is 1,117.61 %. In the previous year, Return on Capital Employed (ROCE) was -166.09 % — a change of -772.89% (higher).

ROCE

1,117.61 %

YoY

-772.89%

Last updated:

In 2025, Biodesix's return on capital employed (ROCE) was 1,117.61 %, a -772.89% increase from the -166.09 % ROCE in the previous year.

The Biodesix ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
11.75 USD
Jan 1, 2019
12.15 USD
Jan 1, 2020
-57.73 USD
Jan 1, 2021
-195.93 USD
Jan 1, 2022
-278.44 USD
Jan 1, 2023
-930.35 USD
Jan 1, 2024
-166.09 USD
Jan 1, 2025
1,117.61 USD
The Biodesix ROCE history
YEARROCEYoY
1,117.61 %-772.89%
-166.09 %-82.15%
-930.35 %+234.13%
-278.44 %+42.11%
-195.93 %+239.41%
-57.73 %-575.03%
12.15 %+3.40%
11.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodesix Stock analysis

What does Biodesix do? Biodesix, Inc. generates revenue through blood-based diagnostic testing services for lung disease patients, including Nodify XL2, Nodify CDT, GeneStrat, and VeriStrat tests. The company also provides SARS-CoV-2 testing services under the Biodesix WorkSafe program, utilizing Bio-Rad SARS-CoV-2 ddPCR, Platelia SARS-CoV-2 Total Ab, and cPass SARS-CoV-2 Neutralizing Antibody tests. Biodesix serves biopharmaceutical companies with diagnostic research, clinical research, development, and testing services, as well as companion diagnostics development and commercialization, all governed by individual contracts with third parties. The primary customers for Biodesix's diagnostic services are patients with lung disease and biopharmaceutical companies seeking specialized testing solutions. The company's artificial intelligence platform supports the discovery and development of clinical solutions for unmet needs in lung disease, enhancing the value of its blood-based tests. Biodesix's focus on lung disease diagnostics and SARS-CoV-2 testing positions it to serve both healthcare providers and pharmaceutical partners in the biotechnology sector. Biodesix's revenue streams include direct patient testing services, SARS-CoV-2 testing programs, and contract-based services for biopharmaceutical companies. The company's blood-based lung cancer tests and SARS-CoV-2 testing options are sold through specific product names and programs, with no mention of additional pricing or subscription models. The business model relies on contractual agreements for services provided outside clinical settings, emphasizing tailored diagnostic solutions for lung disease and infectious disease testing. Biodesix is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Biodesix's Return on Capital Employed (ROCE)

Biodesix's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Biodesix's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Biodesix's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Biodesix’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Biodesix stock

Return on Capital Employed (ROCE) of Biodesix is 1,117.61 % in 2025.

Return on Capital Employed (ROCE) of Biodesix changed from -166.09 % to 1,117.61 %, representing a -772.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Biodesix since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Biodesix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biodesix

All Key Metrics — Biodesix